BRAF and melanoma: The distribution of BRAF and NRAS mutations in this cohort was similar to that in previously reported studies (particularly consistent with stage IV melanoma) with mutually exclusive BRAF-mutants found in 62% and NRAS-mutants in 17% of cases (5,12,16,28).